We calculate performance by dividing numerator by denominator and multiplying by 100 to give a percentage. S09d Karyotype testing for fetal anomaly ultrasound The Down’s syndrome screening quality assurance support service ( DQASS) is commissioned by PHE to support FASP. provide a weekly failsafe process to make sure all screening results, including lower chance results, are communicated to women and the outcome of the discussion recorded Deemed solicitor, REL or RFL owners cannot be added via mySRA and you should follow the process below. Notifications for other individual managers/owners (deemed) All 142 screening services submitted data, including 50 services that reported zero couples at risk.

In Q2 2022 to 2023, national performance of FA4 for inadequate combined samples was 3.9%. FA4 is a KPI where a lower performance is better.All denominators above exclude samples referred for genetic testing where the only indication for testing is an increased NT. FASP recommends all women who accept first trimester screening must have all components of the screening test completed - NT and biochemistry. Performance thresholds Screening for 11 physical conditions as part of the 20-week scan is offered to all pregnant women and takes place between 18⁺⁰ and 20⁺⁶ weeks of pregnancy. Scans can be completed up to 23⁺⁰ weeks of pregnancy. Conditions screened for Denominator: number of samples received for QFPCR testing where the indication for genetic testing is a suspected or confirmed anomaly detected on the 18 weeks plus 0 days to 20 weeks plus 6 days fetal anomaly ultrasound undertaken in the reporting period.

Denominator: number of confirmed cytogenetic diagnoses of T21 following any result (higher or lower chance) from the quadruple test Denominator: number of samples received for karyotype testing where the indication for genetic testing is a suspected or confirmed anomaly detected on the 18 weeks plus 0 days to 20 weeks plus 0 days fetal anomaly ultrasound undertaken in the reporting period.

Who we authorise

Numerator: number of eligible babies who had a completed 20-week screening scan where the specified condition was suspected or confirmed.

National performance of ID1 in Q1 was 99.7%. The national trend graph below shows that ID1 performance has remained above the achievable threshold of 99% since 1 April 2017.

The new standard and KPI

Providers are responsible for reporting identified babies born in their service and those diagnosed or screened in their service (if born elsewhere). T21, T18, T13 higher chance screening result is defined as a result from combined screening for T21 and or T18 and T13, or from quadruple testing for T21 using national cut off. Please be aware that this data covers the time through the COVID-19 pandemic. Provider performance should therefore be interpreted with caution. NCARDRS use a multiple data source approach to improve data completeness and case ascertainment. Reporting period Acceptable level: 90.0% of rapid aneuploidy QFPCR results should be reported within 3 calendar days of sample receipt in the laboratory.

National performance of NB2 (see standard NBS-S06) in Q1 was 2.2%, higher than the previous quarter. The trend graph below shows that England NB2 performance is above the acceptable threshold of 2%. NB2 is a KPI where a lower performance is better. The cohort of women included in this standard is the total number of women in the reporting period who had a suspected or confirmed anomaly at the screening scan. Women are then categorised into either (a) or (b) dependent on the local referral pathway. S08a - local referrals Women who decline is the number of eligible women who are offered screening and make a personal informed choice not to accept screening, including women who choose to have private screening and do not wish to have NHS screening. Performance thresholds To provide assurance of timely information to enable ongoing decisions and or actions. Definition S09a QFPCR testing for higher chance T21, T18, T13 out of 139 screening services submitted data, including 54 services that reported zero women at risk.The proportion of pregnant women eligible for the 20-week screening scan who are tested, leading to a conclusive result within the defined timescale. Rationale Denominator: number of T21, T18, T13 screening samples received in the screening laboratory in the reporting period excluding samples received: All requests for access to FASP data for research purposes need to be approved by the antenatal and newborn screening research advisory committee (RAC). Date standard last updated: 1 April 2020 FASP-S07: referral: time to intervention T21, T18, T13 screening Description